查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594606

以體學為基礎的臨床試驗市場：按階段、研究設計、適應症 - 2025-2030 年全球預測

Omics-Based Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年基於體學的臨床試驗市場價值為301億美元，預計到2024年將達到325.1億美元，複合年成長率為8.39%，到2030年將達到529.2億美元。

基於體學的臨床試驗是精準醫學的關鍵組成部分，它整合了基因組學、蛋白質組學、代謝體學和其他體學技術，根據每個患者獨特的生物學特徵量身定做治療方案。對此類臨床試驗的需求是由於對可以提高療效並最大限度地減少副作用的個人化治療的需求不斷成長而推動的。它應用於藥物開發的各個階段，從生物標記發現到治療反應的患者分層。最終用途包括製藥公司、生物技術公司和學術研究機構，所有這些公司都在利用體學資料來改善臨床結果。市場成長受到高通量測序、資料分析技術進步以及人工智慧在分析複雜資料集不斷擴大的作用的影響。此外，研究機構和製藥公司之間為加速藥物發現而加強的合作研究也支持了市場擴張。然而，資料挑戰之一是與體學資料收集和分析體學的高成本，再加上資料隱私問題和整合多組體學資料集的複雜性，這是昂貴的。資料處理標準化有限也會影響試驗的一致性和可重複性。在這個快速發展的市場中，有開發具有成本效益的資料分析平台和個人化治療解決方案的機會，特別是在體學中顯示出巨大潛力的腫瘤學領域。對強大的生物資訊工具的投資和區域監管協調的努力將支持市場成長。成功的導航需要採用靈活的技術整合方法，同時確保病患資料安全和道德標準。公司可以透過專注於提高基於體學的診斷和治療的準確性和速度來進行創新。在罕見疾病和遺傳疾病等利基應用中，體學可以改變遊戲規則並提供富有洞察力的商機。總體而言，基於體學的臨床試驗市場複雜但前景廣闊，具有巨大的創新和專業化潛力。

主要市場統計
基準年[2023] 301億美元
預測年份 [2024] 325.1億美元
預測年份 [2030] 529.2億美元
複合年成長率（%） 8.39%

市場動態：針對快速發展的基於體學的臨床試驗市場揭示的關鍵市場洞察

基於體學的臨床試驗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 加大醫藥研發領域投入
    • 各種慢性疾病的全球盛行率和負擔不斷增加
    • 對個人化醫療和癌症臨床試驗的日益關注
  • 市場限制因素
    • 基於體學的臨床試驗產品高成本
  • 市場機會
    • 消費者對多組體學解決方案的認知與採用不斷增強
    • 全球併購活動激增
  • 市場挑戰
    • 有效資料分析的問題

波特的五力：駕馭基於體學的臨床試驗市場的策略工具

波特的五力架構是了解基於體學的臨床試驗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基於體學的臨床試驗市場的外部影響

外部宏觀環境因素在塑造基於體學的臨床試驗市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解以體學為基礎的臨床試驗市場的競爭格局

基於體學的臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣組體學臨床試驗市場供應商績效評估

FPNV定位矩陣是評估基於體學的臨床試驗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製基於體學的臨床試驗市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，基於體學的臨床試驗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 加大醫藥研發領域投入
      • 全球各種慢性病的盛行率和負擔不斷增加
      • 更重視個人化醫學和腫瘤學試驗
    • 抑制因素
      • 基於體學的臨床試驗產品高成本
    • 機會
      • 消費者對多組體學解決方案的認知與採用不斷增強
      • 全球併購活動激增
    • 任務
      • 有效資料分析的問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以體學為基礎的臨床試驗市場分階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第7章 以體學為基礎的臨床試驗市場研究設計

  • 擴大訪問研究
  • 干預研究
  • 觀察性研究

第8章以體學的臨床試驗市場（按適應症）

  • 心臟病學
  • 中樞神經系統疾病
  • 遺傳疾病
  • 免疫學
  • 腫瘤學
  • 呼吸系統疾病
  • 皮膚病

第9章美洲基於體學的臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太組體學臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲基於體學的臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Complete Omics, Inc.
  • Covance Inc.
  • Danaher Corporation
  • Eli Lilly and Company
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Merck & Co. Inc.
  • Mission Bio, Inc.
  • NeoGenomics Laboratories, Inc.
  • Novo Nordisk A/S
  • Parexel International Corporation
  • Pfizer, Inc.
  • Rebus Biosystems, Inc.
  • SGS SA
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-3A2E844FD3E0

The Omics-Based Clinical Trials Market was valued at USD 30.10 billion in 2023, expected to reach USD 32.51 billion in 2024, and is projected to grow at a CAGR of 8.39%, to USD 52.92 billion by 2030.

Omics-based clinical trials represent a crucial component of precision medicine, integrating genomics, proteomics, metabolomics, and other omics technologies to tailor therapies towards individual patients' unique biological profiles. The necessity for such trials is driven by the increasing demand for personalized medical treatments, which can improve efficacy and minimize side effects. They are applied across various stages of drug development, from biomarker discovery to patient stratification in treatment responses. End-use scope includes pharmaceuticals, biotechnology companies, and academic research institutions, all leveraging omics data to enhance clinical outcomes. Market growth is influenced by technological advancements in high-throughput sequencing, data analytics, and the expanding role of AI in analyzing complex datasets. Increasing collaborations between research institutions and pharmaceutical companies to accelerate drug discovery also propel market expansion. However, one of the significant challenges is the high cost associated with omics data collection and analysis, coupled with data privacy concerns and the complexity of integrating multi-omics datasets. Limited standardization in data handling also affects trial consistency and reproducibility. Within this rapidly evolving market, opportunities lie in the development of cost-effective data analytics platforms and personalized therapeutic solutions, especially in oncology where omics have shown considerable promise. Investment in robust bioinformatics tools and efforts towards regulatory harmonization across regions can bolster market growth. Successful navigation involves adopting an agile approach to technological integration while ensuring patient data security and ethical standards. Companies can innovate by focusing on improving the accuracy and speed of omics-based diagnostics and treatments. Insightful opportunities await in niche applications like rare diseases and genetic disorders, where omics can make a significant difference. Overall, the market for omics-based clinical trials is complex yet promising, with a substantial capacity for innovation and specialization.

KEY MARKET STATISTICS
Base Year [2023] USD 30.10 billion
Estimated Year [2024] USD 32.51 billion
Forecast Year [2030] USD 52.92 billion
CAGR (%) 8.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Omics-Based Clinical Trials Market

The Omics-Based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising investment in the pharmaceutical research and development sector
    • Increasing prevalence and burden of various chronic diseases globally
    • Growing focus on personalized medicine and oncology trials
  • Market Restraints
    • High cost of omics-based clinical trials products
  • Market Opportunities
    • Upsurging consumer awareness and adoption of multi-omics solutions
    • Proliferation in the number of amalgamation activities across the globe
  • Market Challenges
    • Issues relating to effective data analysis

Porter's Five Forces: A Strategic Tool for Navigating the Omics-Based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Omics-Based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Omics-Based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Omics-Based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Omics-Based Clinical Trials Market

A detailed market share analysis in the Omics-Based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Omics-Based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Omics-Based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Omics-Based Clinical Trials Market

A strategic analysis of the Omics-Based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Omics-Based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include Complete Omics, Inc., Covance Inc., Danaher Corporation, Eli Lilly and Company, ICON Plc, Laboratory Corporation of America Holdings, Merck & Co. Inc., Mission Bio, Inc., NeoGenomics Laboratories, Inc., Novo Nordisk A/S, Parexel International Corporation, Pfizer, Inc., Rebus Biosystems, Inc., SGS SA, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Omics-Based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
  • Based on Indication, market is studied across Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising investment in the pharmaceutical research and development sector
      • 5.1.1.2. Increasing prevalence and burden of various chronic diseases globally
      • 5.1.1.3. Growing focus on personalized medicine and oncology trials
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of omics-based clinical trials products
    • 5.1.3. Opportunities
      • 5.1.3.1. Upsurging consumer awareness and adoption of multi-omics solutions
      • 5.1.3.2. Proliferation in the number of amalgamation activities across the globe
    • 5.1.4. Challenges
      • 5.1.4.1. Issues relating to effective data analysis
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Omics-Based Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. Omics-Based Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. Omics-Based Clinical Trials Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. CNS Diseases
  • 8.4. Genetic Diseases
  • 8.5. Immunology
  • 8.6. Oncology
  • 8.7. Respiratory Diseases
  • 8.8. Skin Diseases

9. Americas Omics-Based Clinical Trials Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Omics-Based Clinical Trials Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Omics-Based Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Complete Omics, Inc.
  • 2. Covance Inc.
  • 3. Danaher Corporation
  • 4. Eli Lilly and Company
  • 5. ICON Plc
  • 6. Laboratory Corporation of America Holdings
  • 7. Merck & Co. Inc.
  • 8. Mission Bio, Inc.
  • 9. NeoGenomics Laboratories, Inc.
  • 10. Novo Nordisk A/S
  • 11. Parexel International Corporation
  • 12. Pfizer, Inc.
  • 13. Rebus Biosystems, Inc.
  • 14. SGS SA
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. OMICS-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OMICS-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OMICS-BASED CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY CNS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM OMICS-BASED CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. OMICS-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. OMICS-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023